Raymond James analyst Christopher Raymond upgraded Ardelyx (ARDX) to Strong Buy from Outperform with a price target of $14, up from $12, after assuming coverage the name. The firm views Ardelyx as a strong commercial execution story that is trading at historically discounted valuation. The stock could break out of its range-bound trading pattern under the new management team as Xphozah growth picks up, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx’s Strong Financial Performance and Strategic Positioning Drive Buy Rating and Increased Price Target
- Ardelyx price target raised to $9 from $8 at Piper Sandler
- Ardelyx Inc. Faces Financial Uncertainty Amid Shifting Trade Policies
- Ardelyx Inc. Q2 2025 Earnings Call Highlights
- Ardelyx price target raised to $14 from $13 at Wedbush